In July 2026, China approved a novel drug targeting a key brain receptor linked to narcolepsy type 1, a chronic neurological sleep disorder defined by excessive daytime sleepiness and sudden muscle weakness. The drug, developed for adolescents aged 16 and older and adults, became available in China first.
It marked a historic milestone: China is no longer a follower in global drug development; it's becoming a major contributor.